RSV Vaccines for the World

14-16 October 2013, Tiara Park Atlantico Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Wednesday 16th October

SESSION 10:
RSV VACCINES: NEW APPROACHES AT THE PRECLINICAL STAGE OF DEVELOPMENT – PART I

Moderator: Sylvia van Drunen Little-van den Hurk (VIDO, University of Saskatchewan, Canada)

08.40-09.00
‘Evaluation of a virosomal Respiratory Syncytial Virus vaccine adjuvanted with monophosphoryl lipid A in cotton rats’
Toon Stegmann and Sylvain Fleury (Mymetics Corporation, Epalinges, Switzerland)

09.00-09.20
‘Assessment of virus-like particle vaccine candidates Respiratory Syncytial Virus’
Trudy Morrison, Madelyn R. Schmidt, Lori W. McGinnes, Sarah Kenward and Robert Woodland (University of Massachusetts, Worcester, Massachusetts, USA)

09.20-09.40
‘Vaccination with the RSV fusion protein formulated with a novel combination adjuvant induces long-lasting protective immunity’
Sylvia van Drunen Little-van den Hurk, R. Garg, L. Latimer, R. Brownlie, V. Gerdts and A. Potter (VIDO, University of Saskatchewan, Canada)

09.40-10.00
‘A protective and safe intranasal RSV vaccine based on a recombinant prefusion form of the F protein bound to a bacterium-like particle carrier’
Bert Jan Haijema, Alan Rigter, Ivy Widjaja, Hanneke Versantvoort, Maarten van Roosmalen, Kees Leenhouts, Peter J.M. Rottier and Cornelis A.M. de Haan (Mucosis BV, Groningen, The Netherlands)

10.00-10.20
‘A nanoemulsiuon-inactivated and adjuvanted whole virus RSV vaccine: Immunogenicity and protection in mice and cotton rats following intranasal or intramuscular administration’
Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)

10.20-10.40 Latebreaker:
‘Co-delivery of intranasal viral vaccines with retinyl palmitate corrects impaired mucosal IgA responses in vitamin A deficient hosts’
Julia L. Hurwitz et al. (St. Jude Children’s Research Hospital, Memphis, Tennessee, USA)

10.40-11.00
Coffee Break & Posters

SESSION 11:
RSV VACCINES: NEW APPROACHES AT THE PRECLINICAL STAGE OF DEVELOPMENT – PART II

Moderator: Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)

11.00-11.20
‘DepoVax™ formulated vaccine to RSV targets novel mechanism of action’
Marc Mansour, Marianne Stanford, Lisa MacDonald, Bert Schepens, Koen Sedeyn, Walter Fiers, Alecia MacKay, Valarmathy Kaliaperumal, Bithika Ray, Tara Quinton, Kendall Sharp, Rajkannan Rrajagopalan, Leeladhar Sammatur and Xavier Saelens (Immunovaccine Inc., Halifax, Nova Scotia, Canada)

11.20-11.40
‘Protective efficacy induced by a live, attenuated rBRSV vaccine and a subunit vaccine containing P, M2-1 and N-nanorings displaying epitopes of F and G, against BRSV in calves’
Krister Blodorn, S. Hagglund, J. Fix, C. Dubuquoy, B. Makabi-Panzu, M. Thom, J.L. Roque, E. Karlstam, J.Pringle, J.F. Eleouet, S. Riffault, G. Taylor and J.F. Valarcher (Swedish University of Agricultural Sciences, Uppsala, Sweden)

11.40-12.00
‘She’s a novel target for RSV vaccination’
Bert Schepens, Liesbeth Vande Ginste, Sarah De Baets, Koen Seydyen, Iebe Rossey, Pieter Bogaert, Brian Gilbert, Pedro A Piedra, Water Fiers and X. Saelens (Ghent University/VIB, Ghent, Belgium)

12.00-12.20
‘Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization’
Cyril le Nouen, Linda G. Brock, Cindy Luongo, Thomas McCarty, Lijuan Yang, Eckard Wimmer, Steffen Mueller, Peter L. Collins, Ursula J. Buchholz and Joshua M. DiNapoli (NIAID/NIH, Bethesda, Maryland, USA)

12.20-12.40
‘Respiratory Syncytial Virus with codon-deoptimized NS1 and NS2 genes is attenuated and immunogenic’
Jia Meng, Sujin Lee and Martin L. Moore (Emory University, Atlanta, Georgia, USA)

12.40-13.00
‘Developing a recombinant adenovirus carrying F protein of RSV as a vaccine for preventing lower respiratory infections caused by RSV’
Yen-Hung Chow and Hsiao-Yun Shao (National Health Research Institutes, Zhunan Town, Taiwan)

13.00-14.00
Lunch Break & Posters Breakdown

SESSION 12:
RSV PROTECTION USING NON-VACCINE APPROACHES & LATE BREAKER PRESENTATIONS

Moderator: Martin Friede (WHO, Geneva, Switzerland)

14.00-14.20
‘Development of affordable immunoprophylaxis against RSV’
Martin Friede (WHO, Geneva, Switzerland)

14.20-14.40
‘Development of ALX-0171, an inhaled Nanobody® for the treatment of respiratory syncytial virus infection in infants’
Erik Depla (Ablynx NV, Zwijnaarde, Belgium)

14.40-15.00
‘Polyclonal human IVIG with standardized high-levels of RSV neutralizing antibodies: A summary of animal and human studies’
Ann R. Falsey, Edward E. Walsh and James J. Mond (Rochester General Hospital, Rochester, New York, USA)

15.00-15.20
‘Correlation of RSV neutralizing antibody with protection against RSV lower respiratory tract illness: Results from an RSV-IGIV prevention trial’
Eric Simoes et al. (University of Colorado, Aurora, Colorado, USA)

15.20-15.40
‘Identification of respiratory syncytial virus A and B strains lacking most of the G protein ecto domain in immunocompromised patients hospitalized with severe acute respiratory illness in South Africa’
Marietjie Venter, Marthi A. Pretorius and Florette Treurnicht (NHLS, Johannesburg, South Africa)

15.40-16.00
Tea Break

16.00-17.00

SESSION 13:
EXTRA SPECIAL PANEL DISCUSSION SESSION

‘Defining clinical endpoints for efficacy trials in various target populations’
Moderator: Cheryl Keech (PATH, Seattle, Washington, USA)

Panelists:
Ruth A. Karron (The Johns Hopkins University, Baltimore, Maryland, USA)
James Nokes (KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK)
Edward E. Walsh (Rochester General Hospital, Rochester, New York, USA)
Janet Englund (Seattle Children’s Hospital, Seattle, Washington, USA)

17.00
Closing Remarks & Departure

* This final programme is correct at the time of publishing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final programme.

 

RSVVW 2013 Sponsors

  • Sanofi Pasteur
  • NanoBio
  • PATH
  • Ablynx
  • Mucosis
  • Pevion Vaccines
  • Okairos
  • Immunovaccine
  • VLP Biotech
  • Aldevron
  • NatureGeneTherapy.com
  • Aldevron
  • Novavax
  • Mymetics
  • Novartis Vaccines
  • Crucell
  • Retroscreen Virology
  • Inovio Pharmaceuticals
  • ADMA Biologics

RSVVW 2013 Downloads

RSVVW 2013 Leaflet

RSVVW 2013 Mailing List

Name
E-mail Address
What is 1+4-2?